Phase 4 N=1,504 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
Nicotine Dependence
Primary: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed — 90; 87; 107; 84 participants with<10 ppm exhaled CO
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
N/A N=103 Smoking Cessation in Alcoholics
Smoking Cessation · Alcohol Consumption
Primary: Number of Smoke-free Patients — 0; 3 participants — p==.111
Phase 4 N=1,346 Smoking Cessation Intervention: Effectiveness in Primary Care
Tobacco Dependence
Primary: 6 Month Self-reported Abstinence From Smoking — 50; 52; 45; 75 participants
Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
N/A N=154 Enhancing a High School Based Smoking Cessation Program
Nicotine Dependence
Primary: Abstinence Rates at the End of Treatment — 35.1; 24.3; 38.6; 36.1 percentage of participants not smoking
N/A N=51 Health-Kit Enabled Mobile App for Tobacco Cessation
Cigarette Smoking
Primary: Psychosocial Expectancies (PROMIS Smoking Initiative) Patient Reported Outcome — 12.7; 13.6 score on a scale — p=0.17
Phase 4 N=52 Tobacco Treatment Comparison for Cancer Care
Smoking Cessation · Cancer
Primary: Biochemically Verified 7-day Point-prevalence Abstinence 26 Weeks After a Target Quit Date. — 2; 7 Participants
Phase 2 N=246 Selegiline for Smoking Cessation - 1
Nicotine Dependence
Primary: Quit Rate — 18; 15 participants
Phase 4 N=1,270 Smoking Cessation in Hospitalized Smokers
Smoking Cessation
Primary: Percentage of Participants With 30-day Abstinence — 18.0; 23.4; 22.1; 18.7 percentage of participants
N/A N=300 Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers
Tobacco Use Disorder
Primary: Quit Rate — 13; 23 Participants
N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants
Phase 4 N=887 Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts
Tobacco Use Disorder · Smoking · Smoking Cessation
Primary: 7-day Point Prevalence of Abstinence — 45; 22; 50 Participants
Phase 4 N=432 Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
Tobacco Use Cessation
Primary: Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco — 125; 85 participants — p=<0.0001
N/A N=56 Engaging Patients in Tobacco Cessation Resources in Dental Settings
Smoking
Primary: Percentage of Smokers With Delivery of Brief Interventions and/or Referral to Treatment — 7; 36 Participants
Phase 3 N=750 Disease Management for Smoking Cessation
Smoking Cessation
Primary: 7-day Point Prevalence Abstinence From Cigarettes — 68; 56; 56 Participants — p=0.54
Phase 4 N=112 Smoking Cessation Treatment for Methadone Maintenance Patients
Smoking Cessation · Substance-Related Disorders
Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03
Phase 4 N=270 Helping Those With Mental Illness Quit Smoking
Smoking · Nicotine Dependence · Mental Disorders
Primary: Acceptance of Wisconsin Tobacco Quit Line Services — 11; 6; 6 participants
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
N/A N=158 Innovative Digital Therapeutic for Smoking Cessation
Smoking Cessation · Nicotine Addiction · Drug Addiction
Primary: 30-Day Sustained Abstinence From Smoking — 69; 66; 10; 13 Participants
Phase 2 N=118 St. John's Wort for Tobacco Cessation
Smoking · Nicotine Dependence
Primary: Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco — 7; 8; 6 participants — p=0.52
Phase 4 N=637 Identifying Optimal Smoking Cessation Intervention Components (Cessation)
Smoking · Smoking Cessation · Nicotine Dependence
Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 208; 209; 201; 216 participants — p=.341
N/A N=1,094 Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Smoking Cessation
Primary: Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey — 13.0; 13.5 percentage of participants — p=0.865
N/A N=91 Promoting Evidenced-Based Tobacco Smoking Cessation Treatment in Community Mental Health Clinics
Tobacco Smoking
Primary: Provider (Staff) Knowledge of Smoking Cessation Treatment as Assessed by a 16-item Scale — 13.8; 14.2 score on a scale
Phase 4 N=490 Varenicline and Combined NRT for Smoking Cessation
Cigarette Smoker · Tobacco Use Disorder
Primary: Smoking Abstinence — 42; 63; 7; 7 Participants
N/A N=6,009 Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)
Smoking
Primary: Count of Participants Not Smoking — 766 Participants
Phase 4 N=312 Smoking Cessation Study In Healthy Adolescent Smokers
Smoking Cessation
Primary: 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12 — 20.2; 27.2; 18.0 percentage of participants — p=0.6337
Phase 2 N=45 Effects of Random Nicotine Delivery on Smoking Cessation
Smoking Cessation · Cigarette Smoking · Smoking (Tobacco) Addiction
Primary: Change in Number of Cigarettes Smoked Per Day (CPD) — -10.3; -9.0; -7.6 cigarettes per day — p=.55
Phase 3 N=504 Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
Smoking Cessation
Primary: Number of Subjects With Four Week Continuous Quit Rate (CQR) — 105; 22 participants — p=<0.0001
Phase 1 N=58 Persistence-Targeted Smoking Cessation
Tobacco Use Disorder
Primary: 7-day Point Prevalence Abstinence — 4; 1 participants